Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence. Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Adv
Hoofdauteurs: Kent, Andrew, Vasu, Sumithira, Schatz, Derek, Monson, Natalie, Devine, Steven, Smith, Clayton, Gutman, Jonathan A., Pollyea, Daniel A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2020
Onderwerpen:
Stimulus Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362348/
https://ncbi.nlm.nih.gov/pubmed/32634235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001991
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items